In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate

Author(s): Mona Sadat Larijani, Seyed Mehdi Sadat, Azam Bolhassani, Mohammad Hassan Pouriayevali, Golnaz Bahramali*, Amitis Ramezani*.

Journal Name: Current HIV Research

Volume 16 , Issue 5 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Acquired immune deficiency syndrome (HIV/AIDS) has been a major global health concern for over 38 years. No safe and effective preventive or therapeutic vaccine has been developed although many products have been investigated. Computational methods have facilitated vaccine developments in recent decades. Among HIV-1 proteins, p24 and Nef are two suitable targets to provoke the cellular immune response. However, the fusion form of these two proteins has not been analyzed in silico yet.

Objective: This study aimed at the evaluation of possible fusion forms of p24 and Nef in order to achieve a potential therapeutic subunit vaccine against HIV-1.

Method: In this study, various computational approaches have been applied to predict the most effective fusion form of p24-Nef including CTL (Cytotoxic T lymphocytes) response, immunogenicity, conservation and population coverage. Moreover, binding to MHC (Major histocompatibility complex) molecules was assessed in both human and BALB/c.

Results: After analyzing six possible fusion protein forms using AAY linker, we came up with the most practical form of p24 from 80 to 231 and Nef from 120 to 150 regions (according to their reference sequence of HXB2 strain) using an AAY linker, based on their peptides affinity to MHC molecules which are located in a conserved region among different virus clades. The selected fusion protein contains seventeen MHC I antigenic epitopes, among them KRWIILGLN, YKRWIILGL, DIAGTTSTL and FPDWQNYTP are fully conserved between the virus clades. Furthermore, analyzed class I CTL epitopes showed greater affinity binding to HLA-B 57*01, HLA-B*51:01 and HLA-B 27*02 molecules. The population coverage with the rate of >70% coverage in the Persian population supports this truncated form as an appropriate candidate against HIV-I virus.

Conclusion: The predicted fusion protein, p24-AAY-Nef in a truncated form with a high rate of T cell epitopes and high conservancy rate among different clades, provides a helpful model for developing a therapeutic vaccine candidate against HIV-1.

Keywords: HIV-1 vaccine, p24-Nef-fusion protein, truncated protein, cytotoxic T lymphocytes, combination antiretroviral therapy, major histocompatibility complex.

[1]
Koff WC. A shot at AIDS. Curr Opin Biotechnol 2016; 42: 147-51.
[2]
HIV/AIDS JUNPo. UNAIDS. 2017.
[3]
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367(5): 399-410.
[4]
Shin SY. Recent update in HIV vaccine development. Clin Exp Vaccine Res 2016; 5(1): 6-11.
[5]
Pollara J, Easterhoff D, Fouda GG. Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 2017; 12(3): 216-21.
[6]
M Barry S. Trial, Error, and Breakthrough: A Review of HIV Vaccine Development. J AIDS Clin Res 2014; 05(11)
[7]
Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2006; 13: 100-6.
[8]
David M. Knipe PH. Fields Virology sixth edition 2013.
[9]
Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381(9883): 2109-17.
[10]
Bayon E, Morlieras J, Dereuddre-Bosquet N, et al. Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates. NPJ Vaccines 2018; 3(1): 46.
[11]
Yasmin T, Akter S, Debnath M, et al. In silico proposition to predict cluster of B- and T-cell epitopes for the usefulness of vaccine design from invasive, virulent and membrane associated proteins of C. jejuni. In Silico Pharmacol 2016; 4(1): 5.
[12]
Munson P, Liu Y, Bratt D, et al. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. Hum Vaccin Immunother 2018; 14(7): 1820-31.
[13]
Shamriz S, Ofoghi H. Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant. BMC Bioinformatics 2016; 17: 71.
[14]
Liu Y, Rao U, McClure J, et al. Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 2014; 9(4): e94240.
[15]
Courant T, Bayon E, Reynaud-Dougier HL, et al. Tailoring nanostructured lipid carriers for the delivery of protein antigens: Physicochemical properties versus immunogenicity studies. Biomaterials 2017; 136: 29-42.
[16]
McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012; 13: 423.
[17]
Viraj Kulkarni AV. Margherita Rosati, Morgane Rolland, James I. Mullins, George N. Pavlakis. HIV-1 Conserved Elements p24CE DNA Vaccine Induces Humoral Immune Responses with Broad Epitope Recognition in Macaques. PLoS One 2014; 9(10)
[18]
Rolland M, Heckerman D, Deng W, et al. Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads. PLoS One 2008; 3(1): e1424.
[19]
Awad-Elkareem MA-E, Osman SA, Mohamed HA, et al. Prediction and Conservancy Analysis of Multiepitope Based Peptide Vaccine Against Merkel Cell Polyomavirus: An Immunoinformatics Approach. Immunol Res 2017; 13: 134.
[20]
He L, Zhu J. Computational tools for epitope vaccine design and evaluation. Curr Opin Virol 2015; 11: 103-12.
[21]
Hekmat SS, Siadat SD, Aghasadeghi MR, et al. From in-silico immunogenicity verification to in vitro expression of recombinant Core-NS3 fusion protein of HCV. Bratisl Med J 2017; 118(04): 189-95.
[22]
Steers NJ, Peachman KK, McClain SR, Alving CR, Rao M. Human Immunodeficiency Virus Type 1 Gag p24 Alters the Composition of Immunoproteasomes and Affects Antigen Presentation. J Virol 2009; 83: 7049-61.
[23]
Krupkaa M, Zachova K, Cahlikovaa R, et al. Endotoxin-minimized HIV-1 p24 fused to murine hsp70 activatesdendritic cells, facilitates endocytosis and p24-specific Th1 responsein mice. Immunol Lett 2015; 166: 36-44.
[24]
Gandhi RT, Kwon DS, Macklin EA, et al. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 2016; 71(3): 246-53.
[25]
Pankrac J, Klein K, McKay PF, et al. A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ Vaccin 2018; 3(1): 40-6.
[26]
Freed EO. HIV-1 assembly, release and maturation. Nat Rev Microbiol 2015; 13: 484.
[27]
Dai B, Xiao L, Bryson PD, Fang J, Wang P. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol Ther 2012; 20(9): 1800-9.
[28]
Molly A. Accola SHG, Heinrich G. Go Ttlinger. A Putative a-Helical Structure Which Overlaps the Capsid-p2 Boundary in the Human Immunodeficiency Virus Type 1 Gag Precursor Is Crucial for Viral Particle Assembly. J Virol 1998; 72: 2072-8.
[29]
Bowzard JB, Bennett RP, Krishna NK, Ernst SM, Rein A, Wills JW. Importance of Basic Residues in the Nucleocapsid Sequence for Retrovirus Gag Assembly and Complementation Rescue. J Virol 1998; 72: 9034-44.
[30]
Alin K, Goff SP. Amino Acid Substitutions in the CA Protein of Moloney Murine Leukemia Virus That Block Early Events in Infection. Virology 1996; 222: 339-51.
[31]
Foster JL, Garcia JV. HIV-1 Nef: at the crossroads. Retrovirology 2008; 5: 84.
[32]
Foster JL, Garcia JV. Role of Nef in HIV-1 replication and pathogenesis. Adv Pharmacol 2007; 55: 389-409.
[33]
Simmons A, Aluviahare V, McMichael A. Nef Triggers a Transcriptional Program in T Cells Imitating Single-Signal T Cell Activation and Inducing HIV Virulence Mediators. Immunity 2001; 14: 763-77.
[34]
Maccormac LPJ. Jean-Marc Chain, Benjamin. The functional consequences of delivery of HIV-1 Nef to dendritic cells using an adenoviral vector. Vaccine 2004; 22(3-4): 528-35.
[35]
Chen DY, Balamurugan A, Ng HL, Cumberland WG, Yang OO. Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes. Blood 2012; 120(1): 100.
[36]
Shinya E, Owaki A, Shimizu M, et al. Endogenously expressed HIV-1 nef down-regulates antigen-presenting molecules, not only class I MHC but also CD1a, in immature dendritic cells. Virology 2004; 326(1): 79-89.
[37]
Pawlak EN, Dikeakos JD. HIV-1 Nef: a master manipulator of the membrane trafficking machinery mediating immune evasion. Biochimica et Biophysica Acta (BBA) - General Subjects. Biochim Biophys Acta 2015; 1850(4): 733-41.
[38]
Mangasarian A, Piguet V, Wang JK, Chen YL, Trono D. Nef-Induced CD4 and Major Histocompatibility Complex Class I (MHC-I) Down-Regulation Are Governed by Distinct Determinants: N-Terminal Alpha Helix and Proline Repeat of Nef Selectively Regulate MHC-I Trafficking. J Virol 1999; 73: 1964-73.
[39]
Hung CH, Thomas L, Ruby CE, et al. HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I. Cell Host Microbe 2007; 19: 121-33.
[40]
Khalili S, Jahangiri A, Borna H, Ahmadi Zanoos K, Amani J. Computational vaccinology and epitope vaccine design by immunoinformatics. Acta Microbiol Immunol Hung 2014; 61(3): 285-307.
[41]
Wong TM, Ross TM. Use of computational and recombinant technologies for developing novel influenza vaccines. Exp Rev Vaccin 2016; 15(1): 41-51.
[42]
Tamura KSG, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Mol Biol Evol 2013; 30: 2725-9.
[43]
Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004; 56: 405-19.
[44]
Stranzl T, Larsen MV, Lundegaard C, Nielsen M. NetCTLpan: Pan-specific MHC class I pathway epitope predictions. Immunogenetics 2010; 62: 357-68.
[45]
Giguere S, Drouin A, Lacoste A, Marchand M, Corbeil J, Laviolette F. MHC-NP: Predicting peptides naturally processed by the MHC. J Immunol Methods 2013; 400-401: 30-6.
[46]
Abroun SFM. Iran Royan Cord Blood Bank: Royan Cord Blood Banking; 2010.
[47]
Shaiegan MYF, Abolghasemi H, Bagheri N, et al. Allele Frequencies of HLA-A, B and DRB1 among People of Fars Ethnicity Living in Tehran. IJBC 2011; pp. 55-9.
[48]
Esmaeili A, Rabe SZT, Mahmoudi M, Rastin M. Frequencies of HLA-A, B and DRB1 alleles in a large normal population living in the city of Mashhad, Northeastern Iran. Iran J Basic Med Sci 2017; 20(8): 940-3.
[49]
Doytchinova IA, Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine 2007; 25: 856-66.
[50]
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007; 8: 4.
[51]
Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007; 8: 361.
[52]
Gupta S, Kapoor P, Chaudhary K, et al. In Silico Approach for Predicting Toxicity of Peptides and Proteins. PlosS One 2013. 8(9): e73957.
[53]
Wilkins MR, Gasteiger E, Bairoch A, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 1999; 112: 531-52.
[54]
Geourjon C. Deleage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Comput Appl Biosci 1995; 11: 681-4.
[55]
Cuff JA, Clamp ME, Siddiqui AS, Finlay M, Barton GJ. JPred: a consensus secondary structure prediction server. Bioinformatics 1998; 14: 892-3.
[56]
Ferrè F, Clote P. DiANNA: a web server for disulfide connectivity prediction. Nucleic Acids Res 2005; 33: W230-2.
[57]
Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008; 9: 40.
[58]
Yuedong Yang YZ. Specific interactions for ab initio folding of protein terminal regions with secondary structures. Proteins 2008; 72: 793-803.
[59]
Laskowski RA, Macarthur MW, Moss DS, Thornton JM. PROCHECK -a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26: 283-91.
[60]
Colovos C, Yeates TO. Verification of protein structures: patterns of non-bonded atomic interactions. Protein Sci 1993; 9: 1511-9.
[61]
Bowie JU, Luthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science 1991; 253: 164-70.
[62]
Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25(13): 1605-12.
[63]
Nickle DC, Rolland M, Jensen MA, et al. Coping with Viral Diversity in HIV Vaccine Design. PLOS Comput Biol 2007; 3(4): e75.
[64]
Nandy A, Basak SC. A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci 2016; 17(5): 666.
[65]
Perez-Martinez AP, Ong E, Zhang L, Marrs CF, He Y, Yang Z. Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa. Infection, Genetics and Evolution 2017; 55: 244-50.
[66]
Afzal S, Idrees M, Hussain M. De Novo modeling of Envelope 2 protein of HCV isolated from Pakistani patient and epitopes prediction for vaccine development. J Transl Med 2014; 12(1): 115.
[67]
Rappuoli R, Bottomley MJ, D’Oro U, Finco O, De Gregorio E. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. JEM 2016; 213(4): 469.
[68]
Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013; 8(3): 360-76.
[69]
Mahdavi M, Ebtekar M, Azadmanesh K, et al. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model. Acta Virol 2010; 54: 131-6.
[70]
Gonzalez-Rabade N, McGown EG, Zhou F, et al. Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice. Plant Biotechnol J 2011; 9: 629-38.
[71]
Kuo LS, Baugh LL, Denial SJ, et al. Overlapping effector interfaces define the multiple functions of the HIV-1 Nef polyproline helix. Retrovirology 2012; 9: 47.
[72]
Popov S, Popova E, Inoue M, Gottlinger HG. Human immunodeficiency virus type 1 Gag engages the Bro1 domain of ALIX/AIP1 through the nucleocapsid. J Virol 2008; 82(3): 1389-98.
[73]
Jia X, Singh R, Homann S, et al. Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. Nat Struct Mol Biol 2012; 19: 701.
[74]
Wonderlich ER, Leonard JA, Collins KL. HIV immune evasion disruption of antigen presentation by the HIV Nef protein. Adv Virus Res 2011; 80: 103-27.
[75]
Hanna E, Hoyne GF. The Role of the Nef Protein in MHC-I Downregulation and Viral Immune Evasion by HIV-1. J Clin Cell Immunol 2015; 7: 375.
[76]
Abdel-Motal UM, Wang S, Awad A, et al. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine 2010; 28(7): 1758-65.
[77]
Piguet V, Wan L, Borel C, et al. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000; 2: 163-7.
[78]
Burinston MT, Cimarelli A, Colgan J, Curtis SP, Luban J. Human Immunodeficiency Virus Type 1 Gag Polyprotein Multimerization Requires the Nucleocapsid Domain and RNA and Is Promoted by the Capsid-Dimer Interface and the Basic Region of Matrix Protein. J Virol 1999; 73: 8527-40.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 5
Year: 2018
Page: [322 - 337]
Pages: 16
DOI: 10.2174/1570162X17666190102151717

Article Metrics

PDF: 38
HTML: 6
EPUB: 1
PRC: 1